GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Esperion Therapeutics
Esperion Therapeutics is a pharmaceutical company focused on cholesterol-lowering drugs. Its stock price tells the story of the battle for share in the vast cardiovascular market. The chart reflects FDA decisions, sales volumes, and competition from blockbusters from pharmaceutical giants.
Share prices of companies in the market segment - Heart
Esperion Therapeutics specializes in the development and commercialization of oral medications to lower "bad" cholesterol. We classify it as part of the "Heart Disease" segment, a key pharmaceutical company. The chart below shows the overall dynamics of this sector, where there is a high demand for new, effective medications.
Broad Market Index - GURU.Markets
Esperion Therapeutics is a pharmaceutical company specializing in the development and commercialization of oral cholesterol-lowering medications. A major player in cardiology, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Esperion's performance to assess the state of the sector.
Change in the price of a company, segment, and market as a whole per day
ESPR - Daily change in the company's share price Esperion Therapeutics
Shares of Esperion, a biopharmaceutical company, exhibit high volatility, as measured by change_co. This metric reflects the sensitivity to sales of its cholesterol-lowering drugs. This metric is a key component of the formulas on System.GURU.Markets for analyzing the pharmaceutical sector.
Daily change in the price of a set of shares in a market segment - Heart
Esperion Therapeutics, Inc. is a pharmaceutical company. This chart highlights the sector's high volatility. Comparing it to ESPR, which focuses on cholesterol treatments, helps assess its risk relative to more diversified pharmaceutical companies.
Daily change in the price of a broad market stock, index - GURU.Markets
Esperion is a biopharmaceutical company specializing in cholesterol-lowering drugs. Cardiology is a risky area of research. The chart below illustrates the high volatility typical of the biotech sector, reflecting the stakes associated with Esperion's developments.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Esperion Therapeutics
Esperion Therapeutics's share price performance over the past year is a biotech company's journey to commercial success. Its market cap fluctuations reflect the battle for market share in cholesterol-lowering drugs. Key factors include sales volumes, regulatory decisions, and competition with pharmaceutical giants, all of which determine its market valuation.
Annual dynamics of market capitalization of the market segment - Heart
Esperion Therapeutics, Inc. is a commercial pharmaceutical company specializing in the development and marketing of non-statin cholesterol-lowering medications. This chart shows how its battle for market share with pharmaceutical giants and efforts to increase sales are impacting its volatile performance.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Esperion is a biopharmaceutical company whose stock performance is driven by sales success of its cholesterol-lowering drugs and progress in research. The company's business is not dependent on economic cycles. This chart reflects biotech events, not macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Esperion Therapeutics
Esperion, a pharmaceutical company, depends on the success of its drugs for its growth. The monthly fluctuations on the chart reflect sales data for its cholesterol-lowering drugs, which demonstrate how well it competes in the vast and established cardiology market.
Monthly dynamics of market capitalization of the market segment - Heart
This chart reflects the dynamics of the biotech sector. For Esperion, a commercial company, it's the backdrop. Its movements illustrate how its cholesterol-lowering drugs compete in a massive market and how sales data influence its valuation.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Esperion Therapeutics is a pharmaceutical company specializing in the development and commercialization of non-statin cholesterol-lowering drugs. This full-market chart allows you to assess how Esperion's shares are performing after transitioning from development to commercial growth, and how its unique product allows it to withstand overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Esperion Therapeutics
Esperion, a pharmaceutical company focused on cholesterol-lowering drugs, is sensitive to news. Weekly stock performance reflects sales data, insurance company decisions, and clinical trial results.
Weekly dynamics of market capitalization of the market segment - Heart
Esperion, like other companies in its sector, is susceptible to general biotech sentiment. However, its focus on cholesterol-lowering drugs makes it sensitive to news from major pharma companies in the same field. The chart shows how Esperion performs in light of these broad-based developments in its therapeutic niche.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Esperion Therapeutics, as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on the commercial success of its drugs and the decisions of insurance companies. The chart below clearly demonstrates how ESPR shares can live their own life, separate from the broader market.
Market capitalization of the company, segment and market as a whole
ESPR - Market capitalization of the company Esperion Therapeutics
Esperion's market capitalization dynamics are a focused story of the fight against cholesterol. This pharmaceutical company's chart reflects the commercial success of its drugs designed for patients who cannot take statins. Its movements reflect Wall Street's assessment of sales volumes and competition in the vast cardiovascular market.
ESPR - Share of the company's market capitalization Esperion Therapeutics within the market segment - Heart
Esperion Therapeutics is a pharmaceutical company focused on the development and commercialization of non-statin cholesterol-lowering drugs. Its market capitalization reflects its position in the vast cardiology market. The chart below shows how investors view its drug sales and the competition.
Market capitalization of the market segment - Heart
Esperion Therapeutics develops and markets drugs to lower "bad" cholesterol. The chart below shows the market capitalization of the entire cardiology pharmaceutical sector. This represents a vast market aimed at combating one of the leading causes of death worldwide.
Market capitalization of all companies included in a broad market index - GURU.Markets
Esperion Therapeutics is a pharmaceutical company focused on the development and commercialization of non-statin cholesterol-lowering drugs. The company's market capitalization reflects the enormous size of the cardiovascular market. Its market share reflects the weight of alternative therapies available to millions of patients who are unsuitable or unhelpful on statins.
Book value capitalization of the company, segment and market as a whole
ESPR - Book value capitalization of the company Esperion Therapeutics
Esperion Therapeutics is built on intellectual capital. The company's book value, which specializes in cholesterol-lowering drugs, consists of patents for its drugs (Nexletol and Nexlizet) and funds for their commercialization and further research. The chart below shows the financial foundation behind these innovative pills.
ESPR - Share of the company's book capitalization Esperion Therapeutics within the market segment - Heart
Esperion Therapeutics, a biopharmaceutical company, is focused on R&D. Its tangible assets include laboratories developing cardiac drugs. The S_BCap_Seg graph shows its small share of physical infrastructure, which is typical for companies in the research stage.
Market segment balance sheet capitalization - Heart
Biotechnology is a world of contrasts. The graph shows the massive factories of pharmaceutical giants. Esperion, as a development company, has a more streamlined model. Its value lies in its intellectual property rights to cholesterol-lowering drugs, not in its scale of production.
Book value of all companies included in the broad market index - GURU.Markets
Esperion Therapeutics focuses on developing and commercializing drugs to lower "bad" cholesterol. The company's assets are not massive factories, but rather intellectual property and commercial infrastructure. The chart below shows the tangible assets behind these innovative heart-health pills.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Esperion Therapeutics
Esperion's balance sheet consists primarily of cash on hand and the value of patents for its cholesterol drug. The market, however, is assessing its ability to turn this drug into a commercial success, competing with pharma giants. The chart below shows how investors view this "David and Goliath battle."
Market to book capitalization ratio in a market segment - Heart
Esperion Therapeutics specializes in developing cholesterol-lowering drugs. Its value depends on the sales success of its drugs and the results of its research. This chart shows how its market valuation, which reflects the commercial potential of its drugs, relates to its tangible assets.
Market to book capitalization ratio for the market as a whole
Esperion Therapeutics is a pharmaceutical company focused on developing and commercializing drugs to lower LDL cholesterol. Its value is determined by the success of its approved drugs and their ability to compete in the vast cardiovascular market. The chart below shows how the market views its commercial potential.
Debts of the company, segment and market as a whole
ESPR - Company debts Esperion Therapeutics
Esperion Therapeutics, a pharmaceutical company focused on cholesterol-lowering drugs, is managing its debt amid a challenging commercial launch. This chart tells the story of how the company is funding its marketing and R&D efforts to increase sales and achieve profitability.
Market segment debts - Heart
Esperion Therapeutics is a pharmaceutical company focused on developing and commercializing cholesterol-lowering drugs. Bringing a new drug to market and promoting it requires significant expenses. This chart shows how the company's debt burden reflects its transition from development to competing with major players in the vast cardiology market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Esperion Therapeutics
Esperion Therapeutics is focused on developing cholesterol-lowering drugs. Despite having approved drugs, the company continues to invest in marketing and new research. This chart shows how it uses debt to finance its commercial operations and R&D, balancing sales growth with financial risk.
Market segment debt to market segment book capitalization - Heart
Esperion Therapeutics, a pharmaceutical company focused on the development and commercialization of non-statin cholesterol-lowering drugs, has a chart that compares its debt to the overall market capitalization of the sector. It shows how the company finances its commercial activities and clinical research in the highly competitive cardiovascular market.
Debt to book value of all companies in the market
Esperion Therapeutics specializes in developing and commercializing drugs to lower "bad" cholesterol. Bringing a new drug to market requires significant marketing and sales expenditures. This graph of total market debt helps understand the financial environment in which Esperion competes for market share against blockbuster drugs from major pharmaceutical companies.
P/E of the company, segment and market as a whole
P/E - Esperion Therapeutics
This chart for Esperion Therapeutics shows the valuation of a pharmaceutical company focused on developing and commercializing cholesterol-lowering drugs. Profitability depends on the successful sales of its drugs. The metric reflects investor expectations regarding its ability to compete in the vast market for statins and other lipid-lowering drugs.
P/E of the market segment - Heart
Esperion Therapeutics is a pharmaceutical company specializing in the development and commercialization of non-statin drugs for lowering LDL cholesterol. This chart shows the average valuation in the pharmaceutical industry, where investors evaluate the potential of drugs to treat common cardiovascular diseases.
P/E of the market as a whole
Esperion Therapeutics is a pharmaceutical company focused on developing and commercializing drugs to lower "bad" cholesterol. This chart shows the overall market sentiment. Comparisons with it help understand how investors assess the commercial success of Esperion's drugs and its ability to compete with pharmaceutical giants, not just general market trends.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Esperion Therapeutics
This chart for Esperion Therapeutics reflects market expectations for sales of its cholesterol-lowering drugs. It shows how analysts assess the company's ability to compete in the large pharmaceutical market and grow its drug market share, which directly impacts future profitability forecasts.
%20P%2FE%20Esperion%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Esperion-Therapeutics&v=1772624135516 "Chart of the company's future (projected) P/E Esperion Therapeutics")
Future (projected) P/E of the market segment - Heart
Esperion Therapeutics is focused on developing and commercializing non-statin cholesterol-lowering drugs. This chart shows average expectations for the pharmaceutical sector. ESPR's position may indicate how investors view the commercial success of its drugs and its ability to compete in the vast cardiovascular market.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Heart&v=1772624135548 "Future (projected) P/E graph of the market segment - Heart")
Future (projected) P/E of the market as a whole
Esperion Therapeutics develops cholesterol-lowering drugs. The company's success depends on regulatory approval and acceptance by the medical community. While overall investor sentiment is important in this chart, clinical trial data and sales volume are key for Esperion.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772624135585 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Esperion Therapeutics
Esperion Therapeutics specializes in the development and commercialization of non-statin cholesterol-lowering drugs. This chart illustrates the trajectory of the pharmaceutical company as it targets a massive market. Its profit growth is driven by sales of its medications, which doctors prescribe to patients with cardiovascular disease.
Profit of companies in the market segment - Heart
Esperion Therapeutics specializes in the development and commercialization of oral drugs to lower "bad" cholesterol. Profitability in the cardiology pharmaceutical segment depends on the scale of the problem (cardiovascular disease is the number one cause of death) and competition. This chart illustrates how ESPR is competing for its share of this massive market with established giants.
Overall market profit
Esperion Therapeutics, which specializes in cholesterol-lowering drugs, operates in a huge market with consistent demand. The company's success depends on regulatory approval and acceptance by the medical community, not the economic cycle shown in this chart. An aging population and the prevalence of cardiovascular disease provide a stable market.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Esperion Therapeutics
Esperion Therapeutics is focused on developing and commercializing non-statin cholesterol-lowering drugs. This chart reflects analysts' profit forecasts, which are dependent on drug sales and the success of its marketing efforts. This is an assessment of its ability to compete in the vast cardiovascular drug market.
%20profit%20of%20the%20company%20Esperion%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Esperion-Therapeutics&v=1772624135722 "Graph of future (projected) profit of the company Esperion Therapeutics")
Future (predicted) profit of companies in the market segment - Heart
Esperion Therapeutics specializes in the development and commercialization of non-statin drugs for lowering LDL cholesterol. The company targets the vast market of patients with cardiovascular disease. This chart shows the revenue forecast for the cardiology pharmaceutical segment, reflecting expectations for demand for new treatments and the competitive landscape in this field.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Heart&v=1772624135786 "Graph of future (predicted) profits of companies in a market segment - Heart")
Future (predicted) profit of the market as a whole
Esperion Therapeutics develops and commercializes cholesterol-lowering medications. Demand for these medications is driven by medical needs and physician prescriptions, making it relatively unaffected by short-term economic fluctuations. However, overall market conditions may influence insurance companies' decisions about coverage for new medications.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772624135799 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Esperion Therapeutics
Esperion Therapeutics specializes in the development and commercialization of non-statin cholesterol-lowering drugs. The company's revenue depends on the sales volume of its drugs. This chart shows how investors assess its success in competing with pharmaceutical giants and its ability to carve out a niche in the vast cardiovascular drug market.
P/S market segment - Heart
Esperion Therapeutics develops and commercializes non-statin cholesterol-lowering drugs. This chart shows the average revenue estimate for the pharmaceutical industry. It helps us understand how well investors believe the company competes against major players in the vast cardiovascular market.
P/S of the market as a whole
Esperion Therapeutics specializes in developing and commercializing drugs to lower "bad" cholesterol. Its success depends on the acceptance of these medications by doctors and patients. This chart helps understand how the market values the revenue of a pharmaceutical company operating in the vast but highly competitive cardiovascular market.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Esperion Therapeutics
Esperion Therapeutics is a pharmaceutical company specializing in the development and commercialization of cholesterol-lowering drugs. The chart shows a market estimate based on expected future sales and market penetration of its innovative drugs for patients with cardiovascular disease.
%20P%2FS%20Esperion%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Esperion-Therapeutics&v=1772624136044 "The graph of the company's future (projected) P/S Esperion Therapeutics")
Future (projected) P/S of the market segment - Heart
Esperion Therapeutics specializes in the development and commercialization of non-statin cholesterol-lowering drugs. The data in the graph shows the average future sales estimates for pharmaceutical companies. This allows one to assess market expectations for the commercial success of Esperion's drugs and their ability to capture market share in the highly competitive cardiology market.
%20P%2FS%20market%20segment%20graph%20-%20Heart&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Heart&v=1772624136083 "Future (projected) P/S market segment graph - Heart")
Future (projected) P/S of the market as a whole
Esperion Therapeutics is focused on developing and commercializing cholesterol-lowering drugs. This is a huge market, but the company's success depends on its ability to compete with the giants. This indicator of overall revenue expectations is of little importance to the company. The key factors are clinical trial data and the effectiveness of its marketing strategy.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772624136123 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Esperion Therapeutics
Esperion Therapeutics is a pharmaceutical company specializing in the development and commercialization of cholesterol-lowering medications. Revenue, shown in this chart, is directly related to the sales volume of its medications. This growth demonstrates the trust of doctors and patients in its cardiovascular products.
Sales of companies in the market segment - Heart
Esperion Therapeutics is a pharmaceutical company focused on developing and commercializing drugs to lower "bad" cholesterol (LDL). Their medications offer new treatment options for patients who are not responding to traditional statins. This chart shows the sector's total revenue, reflecting the vast market and the ongoing need for new treatments for cardiovascular disease.
Overall market sales
Esperion Therapeutics develops and commercializes drugs to lower "bad" cholesterol. This chart shows the state of the economy, but for ESPR, the primary driver is the prevalence of cardiovascular disease. It is one of the world's leading health problems, and the need for effective treatments is enormous and independent of GDP.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Esperion Therapeutics
Esperion Therapeutics specializes in the development and commercialization of oral medications to lower "bad" cholesterol. The company's sales depend on the acceptance of its medications by the medical community and patients. This chart shows the projected growth in prescriptions and market share for cardiovascular disease.
%20sales%20of%20the%20company%20Esperion%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Esperion-Therapeutics&v=1772624136308 "Schedule of future (projected) sales of the company Esperion Therapeutics")
Future (projected) sales of companies in the market segment - Heart
Esperion Therapeutics specializes in the development and commercialization of oral medications to lower "bad" cholesterol. The company offers an alternative for patients who are not suitable for statins. The chart shows forecasts for the cardiology segment of the pharmaceutical market. Esperion's growth depends on the successful promotion of its drugs among physicians.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Heart&v=1772624136352 "Schedule of future (projected) sales of companies in the market segment - Heart")
Future (projected) sales of the market as a whole
Esperion Therapeutics specializes in developing cholesterol-lowering drugs. The company's commercial success depends on the widespread adoption of its drugs in clinical practice. The overall economic situation, reflected in this chart, influences healthcare budgets and the willingness of insurance companies to cover new, more effective drugs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772624136474 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Esperion Therapeutics
Esperion Therapeutics develops and commercializes drugs to lower "bad" cholesterol. The company's profitability depends on the sales volume of its drugs and the effectiveness of its marketing efforts. This chart shows how the company translates its scientific advances in cardiology into financial results.
Market segment marginality - Heart
Esperion Therapeutics specializes in the development and commercialization of oral drugs to lower "bad" cholesterol. This chart shows the average profitability in the pharmaceutical industry. The company's success and its ability to outperform the average depend on the widespread adoption of its drugs by doctors and patients in the vast cardiovascular market.
Market marginality as a whole
Esperion Therapeutics specializes in the development and commercialization of oral cholesterol-lowering drugs. Its success depends on competing with blockbusters from pharmaceutical giants and on physician acceptance of its medications. This total revenue chart illustrates the challenges for a small company competing for a share of the vast cardiovascular market.
Employees in the company, segment and market as a whole
Number of employees in the company Esperion Therapeutics
For pharmaceutical company Esperion, whose drug has already been approved, commercialization is a key goal. Significant growth on this chart would reflect the creation or expansion of a sales and marketing team necessary to promote the drug to physicians and increase its market share.
Share of the company's employees Esperion Therapeutics within the market segment - Heart
Esperion Therapeutics is focused on the development and commercialization of non-statin cholesterol-lowering drugs. Following approval of its drugs, the company is actively building its commercial team. This chart shows the percentage of specialists (especially in sales and marketing) in the cardiology pharmaceutical segment that Esperion is attracting to bring its products to market.
Number of employees in the market segment - Heart
Esperion Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of non-statin cholesterol-lowering drugs. The company's growth, particularly in its commercial division, which can be seen in the chart, is directly related to its efforts to promote its drugs to physicians and patients following regulatory approval.
Number of employees in the market as a whole
Esperion Therapeutics develops cholesterol-lowering drugs. Cardiovascular disease is a major public health problem, and demand for effective treatments is not dependent on economic cycles, as shown in this chart. Demand for its medications is driven by public health, not the labor market.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Esperion Therapeutics (ESPR)
Esperion Therapeutics is a pharmaceutical company with existing drugs on the market. Its value is determined by both current sales and development potential. This chart reflects its balance sheet. Its market capitalization per employee is high, but lower than that of purely research-based biotech companies due to its commercial staff.
%20of%20the%20company%20Esperion%20Therapeutics%20(ESPR)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Esperion-Therapeutics-ESPR&v=1772624136917 "Chart of market capitalization per employee (in thousands of dollars) of the company Esperion Therapeutics (ESPR)")
Market capitalization per employee (in thousands of dollars) in the market segment - Heart
Esperion Therapeutics specializes in developing and commercializing cholesterol-lowering drugs. The company focuses on a few key drugs, allowing it to operate with a relatively small team. This chart shows how the market values its intellectual property per employee.
%20by%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Heart&v=1772624136981 "Market capitalization per employee (in thousands of dollars) by market segment - Heart")
Market capitalization per employee (in thousands of dollars) for the overall market
Esperion Therapeutics specializes in developing and commercializing cholesterol-lowering drugs. The chart shows the valuation of the pharmaceutical company with its products on the market. It reflects how the market evaluates the balance between potential drug sales and the costs of maintaining a team for research, marketing, and sales.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772624137020 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Esperion Therapeutics (ESPR)
Esperion Therapeutics specializes in cholesterol-lowering drugs. They have commercial products, which sets them apart from many biotechs. This chart shows how successful their commercial model is. It measures how much net profit each employee generates, including the sales team, which competes with pharmaceutical giants.
%20Chart%20Esperion%20Therapeutics%20(ESPR)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Esperion-Therapeutics-ESPR&v=1772624137030 "Company Profit Per Employee (in thousands of dollars) Chart Esperion Therapeutics (ESPR)")
Profit per employee (in thousands of dollars) in the market segment - Heart
Esperion (ESPR) is an R&D biotech (approved cholesterol-lowering drug Nexletol). This chart shows the benchmark for "Heart" (Pharma). The average profit per employee in this sector (biotech) is high (if there's a hit). The benchmark reflects a "one-hit business": the sector spends millions on R&D, and a single successful drug recoups all costs.
%20in%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Heart&v=1772624137092 "Chart of profit per employee (in thousands of dollars) in the market segment - Heart")
Profit per employee (in thousands of dollars) for the market as a whole
Esperion Therapeutics (ESPR) is a pharmaceutical company focused on cholesterol-lowering drugs (LDL). They have approved drugs (Nexletol). This chart shows how effectively the company commercializes its drugs: how much revenue each R&D and sales employee generates in the highly competitive cardiology market.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772624137113 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Esperion Therapeutics (ESPR)
Esperion Therapeutics specializes in cholesterol-lowering medications. This chart shows the commercial success of its drugs. The increase in revenue per employee reflects increased sales volumes, the effectiveness of the marketing and sales team, and the demand for its products in the highly competitive pharmaceutical market.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Esperion-Therapeutics-ESPR&v=1772624137176 "Sales chart per company employee Esperion Therapeutics (ESPR)")
Sales per employee in the market segment - Heart
Esperion (ESPR) is a pharmaceutical company focused on cholesterol-lowering drugs (Nexletol, Nexlizet). They are in the commercialization stage. This chart shows their commercial success. Revenue per employee here is a direct indicator of how successful their sales team is in convincing doctors to prescribe their drugs instead of established statins.
Sales per employee for the market as a whole
Esperion Therapeutics specializes in cholesterol-lowering drugs. As a biotech company, they have completed the R&D phase and are now in the commercialization phase. This metric is critical for them now: it shows how effectively their sales team is promoting the drugs to doctors and how quickly revenue is growing relative to personnel costs.
Short shares by company, segment and market as a whole
Shares shorted by company Esperion Therapeutics (ESPR)
Esperion (ESPR) is a pharmaceutical company focused on cholesterol treatment. They have developed non-statin drugs (Nexletol/Nexlizet) for patients for whom statins are ineffective or contraindicated. This chart shows bearish bets. Bears doubt the commercial success of their drugs: will they be able to compete with cheap generic statins?
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Esperion-Therapeutics-ESPR&v=1772624137295 "Short Shares Chart for the Company Esperion Therapeutics (ESPR)")
Shares shorted by market segment - Heart
Esperion (ESPR) is a pharmaceutical company specializing in drugs to lower LDL cholesterol for patients who cannot tolerate statins. This chart shows the odds against the specialty pharmaceutical sector. The rising odds against the industry reflect investor concerns about the slow commercialization of Esperion's drugs.
Shares shorted by the overall market
Esperion Therapeutics (ESPR) is a pharmaceutical company focused on developing and selling cholesterol-lowering drugs. This chart illustrates the overall market pessimism. Despite having approved products, ESPR is competing with giants. The rising market fear (as shown by the chart) reflects investor concerns about their ability to compete and achieve profitability.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Esperion Therapeutics (ESPR)
Esperion Therapeutics focuses on cholesterol-lowering drugs. The stock is volatile and dependent on R&D and commercial success. This chart can surge above 70 on positive FDA news or sales data. Oversold territory (<30) is often associated with failures, competition, or market entry issues, indicating pessimism.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Esperion-Therapeutics-ESPR&v=1772624137353 "RSI 14 indicator chart for the company's stock Esperion Therapeutics (ESPR)")
RSI 14 Market Segment - Heart
Esperion Therapeutics is a pharmaceutical company focused on cholesterol-lowering drugs (Nexletol) for patients who cannot take statins. Its success depends on acceptance by doctors and insurers. This chart tracks the collective momentum in the cardiovascular (cardio) biotech sector. It helps understand whether ESPR's dynamics are a response to its sales or part of a broader trend in the sector.
RSI 14 for the overall market
Esperion Therapeutics, a biotech company, is critically dependent on sentiment, as reflected in this chart. Market euphoria means open capital markets, making it easy to fund expensive clinical trials. In moments of market panic, investors flee unprofitable biotechs, and companies risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ESPR (Esperion Therapeutics)
Esperion Therapeutics is a pharmaceutical company focused on developing and marketing oral cholesterol-lowering medications. This chart shows the average target price. Analysts' forecasts are based on the growth in prescriptions for the medications (Nexletol/Nexlizet) and their market potential.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ESPR-Esperion-Therapeutics&v=1772624137496 "A chart showing analyst consensus forecasts for the expected stock price. ESPR (Esperion Therapeutics)")
The difference between the consensus estimate and the actual stock price ESPR (Esperion Therapeutics)
Esperion is a pharmaceutical company focused on cholesterol treatment. They have developed non-statin drugs (Nexletol/Nexlizet) that lower LDL cholesterol. They recently achieved indication expansion, opening the market for them. This chart shows how confident analysts are in their ability to finally achieve commercial success.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ESPR-Esperion-Therapeutics&v=1772624137513 "A chart showing the difference between the consensus forecast and the actual stock price. ESPR (Esperion Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Heart
Esperion Therapeutics is a pharmaceutical company focused on cholesterol treatment. It sells pills (Nexletol, Nexlizet) as an alternative for patients who cannot take statins. This chart shows general expectations for the cardiology sector. It reflects whether experts believe non-statin drugs will be commercially successful.
Analysts' consensus forecast for the overall market share price
Esperion Therapeutics is a pharmaceutical company specializing in non-statin drugs for lowering bad cholesterol (LDL). This chart shows overall market sentiment. For Esperion, whose success depends on sales volumes of its drugs in a competitive market, overall optimism is important, but investors are more focused on insurance company decisions and prescription data.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Esperion Therapeutics
Esperion (ESPR) is a pharmaceutical company focused on one goal: lowering LDL (bad) cholesterol. Their drugs (Nexletol/Nexlizet) are a non-statin alternative for patients who aren't achieving their goals. This chart is an assessment of their commercial struggle. It reflects their slow and arduous battle to secure reimbursement from insurance companies and convince doctors to prescribe their drugs.
AKIMA Market Segment Index - Heart
Esperion (ESPR) is a single-product pharmaceutical company; the company developed and markets NEXLETOL, a first-in-class oral (non-statin) cholesterol-lowering drug. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this niche (cholesterol) model (ESPR) differentiate itself from the average pharmaceutical company?
The AKIM Index for the overall market
Esperion is a pharmaceutical company that developed a non-statin drug (Nexletol) for lowering cholesterol. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this commercialization story in cardiology fits in with the overall economic trends affecting healthcare.
